HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term outcome of live donor kidney transplantation for renal amyloidosis.

AbstractBACKGROUND:
The short-term outcome of kidney transplantation in patients with amyloidosis has been reported. The aim of this study is to investigate long-term results in patients with renal amyloidosis.
METHODS:
We studied results of renal transplantation in 23 amyloidotic transplant recipients compared with those in a control group of 47 nonamyloidotic patients. Amyloidosis was secondary to familial Mediterranean fever (FMF) in 16 patients, whereas it was primary (idiopathic) in 7 transplant recipients. The 2 groups were homogeneous regarding age, sex, HLA matching, immunosuppression, and duration of transplantation.
RESULTS:
Five- and 10-year actuarial graft survival rates were similar in both groups (79.35% versus 84.04% and 65.92% versus 56.61%, respectively ). Five- and 10-year actuarial patient survival rates also were similar (80% versus 94% and 68% versus 87%, respectively). Moreover, 72.4% of controls experienced at least 1 rejection episode, whereas only 43.5% of amyloidotic transplant recipients experienced 1 or more such events (P = 0.02). Nonetheless, mean serum creatinine concentrations did not differ between the 2 groups during the observation period. Maintenance colchicine therapy prevented the recurrence of both FMF symptoms and amyloidosis. Recurrence was documented in only 1 amyloidotic transplant recipient (4.3%) 10 years posttransplantation. Significant gastrointestinal (GI) problems were more frequent in amyloidotic patients (65% versus 38%; P = 0.03). Amyloidotic patients with GI problems, except for 2 patients, were administered cyclosporine. Eleven of these patients had FMF, which appeared to reflect the effects of both cyclosporine and colchicine. Infections were similar in the groups; whereas amyloidotic patients had significantly lower blood pressures.
CONCLUSION:
In our experience, long-term (5 to 10 years) outcome of live related donor kidney transplantation in patients with amyloidosis is similar to that in the general transplant population.
AuthorsAli Mohamed Sherif, Ayman Fathi Refaie, Mohamed Abdel-Kader Sobh, Nagi Abdel-Hadi Mohamed, Hussein Atia Sheashaa, Mohamed Ahmed Ghoneim
JournalAmerican journal of kidney diseases : the official journal of the National Kidney Foundation (Am J Kidney Dis) Vol. 42 Issue 2 Pg. 370-5 (Aug 2003) ISSN: 1523-6838 [Electronic] United States
PMID12900821 (Publication Type: Journal Article)
Chemical References
  • Immunosuppressive Agents
  • Cyclosporine
Topics
  • Adolescent
  • Adult
  • Amyloidosis (drug therapy, etiology, surgery)
  • Cyclosporine (therapeutic use)
  • Familial Mediterranean Fever (complications, drug therapy)
  • Female
  • Follow-Up Studies
  • Graft Rejection (epidemiology)
  • Graft Survival
  • Humans
  • Hypertension (complications)
  • Immunosuppressive Agents (therapeutic use)
  • Kidney Failure, Chronic (drug therapy, etiology, surgery)
  • Kidney Transplantation (statistics & numerical data)
  • Life Tables
  • Male
  • Middle Aged
  • Recurrence
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: